These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3797570)

  • 1. Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
    Nuechterlein KH; Snyder KS; Dawson ME; Rappe S; Gitlin M; Fogelson D
    Psychopharmacol Bull; 1986; 22(3):633-9. PubMed ID: 3797570
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expressed emotion, maintenance pharmacotherapy, and schizophrenic relapse among Mexican-Americans.
    Jenkins JH; Karno M; de la Selva A; Santana F; Telles C; Lopez S; Mintz J
    Psychopharmacol Bull; 1986; 22(3):621-7. PubMed ID: 3797568
    [No Abstract]   [Full Text] [Related]  

  • 7. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 8. The dysphoric syndrome in schizophrenia and its implications for relapse.
    Hirsch SR; Jolley AG
    Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Substitution of fluphenazine decanoate with oxyprothepine decanoate in long-term maintenance therapy in schizophrenia].
    David I; Filip V; Hellerová P
    Cesk Psychiatr; 1986 Oct; 82(5):313-7. PubMed ID: 2878734
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 13. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
    Rifkin A; Quitkin F; Kane J; Klein DF
    Psychopharmacol Bull; 1977 Apr; 13(2):49-50. PubMed ID: 323910
    [No Abstract]   [Full Text] [Related]  

  • 16. Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia.
    Kong DS; Yeo SH
    Singapore Med J; 1985 Dec; 26(7):551-5. PubMed ID: 3834613
    [No Abstract]   [Full Text] [Related]  

  • 17. The social value of fluphenazine decanoate.
    Stevens B
    Acta Psychiatr Belg; 1976; 76(5):792-804. PubMed ID: 799897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
    [No Abstract]   [Full Text] [Related]  

  • 20. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B; Palmstierna T
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.